Associated Genetic Biomarkers
GNA11 (guanine nucleotide binding protein (G protein), alpha 11 (Gq class)) is a gene that encodes the guanine nucleotide-binding protein subunit alpha-11, a subunit of one of the heterotrimeric guanine nucleotide binding proteins (G proteins). Oncogenic mutations result in a constitutively active Gα subunit (PMID: 1328859; PMID: 2549426). Receptor activation causes the dissociation of the Gα subunit from Gßγ. Both Gα and Gßγ can then activate downstream cellular signaling pathways (PMID: 1328859; PMID: 2549426).
GNA11 is altered in 0.89% of all cancers with uveal melanoma, lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in GNA11 are GNA11 Mutation (0.64%), GNA11 Exon 5 Mutation (0.26%), GNA11 Loss (0.25%), GNA11 Codon 209 Missense (0.17%), and GNA11 Q209L (0.16%) .
GNA11 status serves as an inclusion eligibility criteria in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain GNA11 status as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
Trials with GNA11 status in the inclusion eligibility criteria most commonly target melanoma, colorectal carcinoma, cutaneous melanoma, malignant solid tumor, and uveal melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is GNA11 Mutation .
Binimetinib, crizotinib, darovasertib, ipilimumab, and nivolumab are the most frequent therapies in trials with GNA11 as an inclusion criteria .
Significance of GNA11 in Diseases
Uveal Melanoma +
GNA11 is altered in 49.22% of uveal melanoma patients .
GNA11 is an inclusion criterion in 2 clinical trials for uveal melanoma, of which 2 are open and 0 are closed. Of the trials that contain GNA11 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) .
Cutaneous Melanoma +
Colorectal Carcinoma +
GNA11 is altered in 0.87% of colorectal carcinoma patients .
GNA11 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Malignant Solid Tumor +
GNA11 is altered in 0.95% of malignant solid tumor patients .
GNA11 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Mucosal Melanoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.